Skip to content
OpenCapital
Get started

Annexon ANNX Available For Sale Securities Debt Securities Current

Available For Sale Securities Debt Securities Current at other companies

Nektar Therapeutics logo
Nektar TherapeuticsNKTR
——
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
——

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$868.37M+223%
Enterprise value$718.59M+261%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×
Current ratio6.4×-1.6×

Where this comes from

Reported directly by Annexon in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's available for sale securities debt securities current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's available for sale securities debt securities current?
Annexon (ANNX) reported available for sale securities debt securities current of $49.82M in Q1 2026.
How has Annexon's available for sale securities debt securities current changed year-over-year?
Annexon's available for sale securities debt securities current decreased by 70.1% year-over-year, from $166.57M to $49.82M.
What is the long-term trend for Annexon's available for sale securities debt securities current?
Over 5 years (2020 to 2025), Annexon's available for sale securities debt securities current has grown at a -1.6% compound annual growth rate (CAGR), from $82.64M to $76.29M.